[go: up one dir, main page]

PT837874E - Esteroides neuroactivos da serie androstano e pregnano - Google Patents

Esteroides neuroactivos da serie androstano e pregnano

Info

Publication number
PT837874E
PT837874E PT96919372T PT96919372T PT837874E PT 837874 E PT837874 E PT 837874E PT 96919372 T PT96919372 T PT 96919372T PT 96919372 T PT96919372 T PT 96919372T PT 837874 E PT837874 E PT 837874E
Authority
PT
Portugal
Prior art keywords
series
derivatives
grc
alpha
hydroxy
Prior art date
Application number
PT96919372T
Other languages
English (en)
Inventor
Ravindra B Upasani
David B Fick
Derk J Hogenkamp
Nancy C Lan
Original Assignee
Euro Celtique Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Euro Celtique Sa filed Critical Euro Celtique Sa
Publication of PT837874E publication Critical patent/PT837874E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J5/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane and substituted in position 21 by only one singly bound oxygen atom, i.e. only one oxygen bound to position 21 by a single bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0007—Androstane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0003—Androstane derivatives
    • C07J1/0018—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa
    • C07J1/0022—Androstane derivatives substituted in position 17 beta, not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0029—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0055—Estrane derivatives not substituted in position 17
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0077—Ethers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J21/00—Normal steroids containing carbon, hydrogen, halogen or oxygen having an oxygen-containing hetero ring spiro-condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring the nitrogen atom being directly linked to the cyclopenta(a)hydro phenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
    • C07J41/005—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of only two carbon atoms, e.g. pregnane derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT96919372T 1995-06-06 1996-06-06 Esteroides neuroactivos da serie androstano e pregnano PT837874E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46740495A 1995-06-06 1995-06-06

Publications (1)

Publication Number Publication Date
PT837874E true PT837874E (pt) 2005-03-31

Family

ID=23855552

Family Applications (1)

Application Number Title Priority Date Filing Date
PT96919372T PT837874E (pt) 1995-06-06 1996-06-06 Esteroides neuroactivos da serie androstano e pregnano

Country Status (23)

Country Link
US (1) US5925630A (pt)
EP (2) EP1288220A3 (pt)
JP (1) JP4145350B2 (pt)
KR (1) KR19990022323A (pt)
CN (1) CN1190404A (pt)
AT (1) ATE284895T1 (pt)
AU (1) AU725214B2 (pt)
BR (1) BR9608592A (pt)
CA (1) CA2223996A1 (pt)
CZ (1) CZ394197A3 (pt)
DE (1) DE69634039T2 (pt)
ES (1) ES2235187T3 (pt)
FI (1) FI974448A0 (pt)
GE (1) GEP20012530B (pt)
HU (1) HUP9901138A3 (pt)
IL (1) IL122348A0 (pt)
NO (1) NO311805B1 (pt)
NZ (1) NZ310850A (pt)
PL (1) PL185523B1 (pt)
PT (1) PT837874E (pt)
RU (1) RU2194712C2 (pt)
UA (1) UA57706C2 (pt)
WO (1) WO1996040043A2 (pt)

Families Citing this family (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070129282A1 (en) * 1998-11-24 2007-06-07 Ahlem Clarence N Pharmaceutical treatments and compositions
WO2000050034A1 (en) * 1999-02-24 2000-08-31 The Regents Of The University Of California Gaba receptors mediate inhibition of t cell responses
EP1449846A1 (en) * 1999-04-29 2004-08-25 Euro-Celtique S.A. 3-alpha Hydroxy-3-beta methoxymethyl-21-heterocycle substituted steriods with anaesthetic activity
RU2243232C2 (ru) * 1999-04-29 2004-12-27 Еро-Сельтик С.А. 3альфа-гидрокси-3бета-метоксиметил-21-гетероцикл-замещенные стероиды, фармацевтическая композиция, способ облегчения или профилактики бессонницы или погружения в наркоз
EP1832598A3 (en) 1999-09-30 2008-01-02 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatment of androgen receptor driven conditions
GB2363983A (en) 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 7-hydroxyepiandrosterone
GB2363984A (en) * 2000-06-29 2002-01-16 Hunter Fleming Ltd Protection against neuronal damage using 3-hydroxy-7 -hydroxy steroids and 3-oxo-7 -hydroxy steroids
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
AR031473A1 (es) * 2000-11-20 2003-09-24 Lundbeck & Co As H Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide
GR1003861B (el) * 2000-12-29 2002-04-11 Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa.
RU2182004C1 (ru) * 2001-02-22 2002-05-10 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Лекарственный препарат для парентерального применения
EP2135611A1 (en) 2001-03-01 2009-12-23 Hollis-Eden Pharmaceuticals Inc. Pregn-5-en-20-yne-3,7,17-triol derivatives for use in therapy
US8569275B2 (en) 2002-08-28 2013-10-29 Harbor Therapeutics, Inc. Steroids having 7-oxgen and 17-heteroaryl substitution
EP1615944A4 (en) * 2003-04-01 2010-08-11 Harbor Biosciences Inc ANTI-ORANGE PROBLEMS WITH MARGINAL AGONIST EFFECT AND METHOD OF USE
CA2580730C (en) * 2003-09-25 2015-01-13 Cenomed, Inc. Tetrahydroindolone derivatives for treatment of neurological conditions
US20050107439A1 (en) * 2003-11-10 2005-05-19 Helton David R. Composition and method for treating emesis
WO2006012563A2 (en) * 2004-07-23 2006-02-02 The Regents Of The University Of California Method for the treatment and diagnosis of certain psychiatric disorders related to the menstrual cycle
RU2289403C2 (ru) * 2004-07-30 2006-12-20 Государственное учреждение Научно-исследовательский институт фармакологии им. В.В. Закусова Российской Академии медицинских наук Фармацевтическая композиция на основе афобазола
EP1807118B8 (en) * 2004-09-29 2014-04-23 Harbor Therapeutics, Inc. Steroid analogs and characterization and treatment methods
US20060211667A1 (en) * 2005-03-21 2006-09-21 Eric Marchewitz Use of pregnane steroid derivatives for enhancing physical performance
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
EP2030622B1 (en) * 2005-03-24 2011-02-23 Emory University Indication of dosage of progesterone in the treatment of a traumatic brain injury
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2625153A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
CA2625210A1 (en) 2005-10-31 2007-05-10 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
AU2007292848A1 (en) 2006-09-08 2008-03-13 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
EP2097437B1 (en) 2006-11-21 2015-05-27 Umecrine Cognition AB The use of pregnane and androstane steroids for the manufacture of a pharmaceutical composition for the treatment of cns disorders
RU2326671C1 (ru) * 2007-03-30 2008-06-20 Государственное образовательное учреждение высшего профессионального образования "БАШКИРСКИЙ ГОСУДАРСТВЕННЫЙ МЕДИЦИНСКИЙ УНИВЕРСИТЕТ Федерального Агентства по здравоохранению и социальному развитию" (ГОУ ВПО БГМУ РОСЗДРАВА) Средство для модуляции дофаминовых рецепторов головного мозга при менопаузе
US20100204192A1 (en) 2007-06-11 2010-08-12 University Of Sourthern California Agents, compositions and methods for enhancing neurological function
JP2010530371A (ja) * 2007-06-11 2010-09-09 ユニバーシティ オブ サザン カリフォルニア 神経学的機能を増強するための作用物質、組成物および方法
EP2219648A4 (en) * 2007-11-09 2010-11-03 Cenomed Biosciences Llc TREATMENT OF POSTRAUMATIC STRESS WITH TETRAHYDROINDOLONE ARYLPIPERAZINE COMPOUNDS
US20090264443A1 (en) * 2008-04-18 2009-10-22 David Helton Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds
CN101585862B (zh) * 2008-05-20 2014-12-17 梅克芳股份公司 甾族化合物
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US9089531B2 (en) 2010-09-28 2015-07-28 The Regents Of The University Of California GABA agonists in the treatment of disorders associated with metabolic syndrome and GABA combinations in treatment or prophylaxis of type I diabetes
WO2012116290A2 (en) 2011-02-25 2012-08-30 Washington University Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same
EP2736919A4 (en) * 2011-07-29 2015-01-14 Univ California NEW 17-BETA-HETEROARYL-SUBSTITUTED STEROIDS AS MODULATORS OF GABAA RECEPTORS
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
CN113234114A (zh) * 2011-10-14 2021-08-10 萨奇治疗股份有限公司 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途
WO2013112605A2 (en) 2012-01-23 2013-08-01 Sage Therapeutics, Inc. Neuroactive steroid formulations and methods of treating cns disorders
US20130281418A1 (en) * 2012-04-23 2013-10-24 Eric D. Marchewitz Use of hydroxypregnenolone derivatives for enhancing health and physical performance
HUE056838T2 (hu) 2012-08-21 2022-04-28 Sage Therapeutics Inc Allopregnanolon makacs epileptikus állapot kezelésére
CN102816198A (zh) * 2012-09-08 2012-12-12 广西师范学院 具有氨衍生物支链结构的3-羟基-5-烯甾体化合物制备方法及其在抗肿瘤药物中的应用
CN102924554B (zh) * 2012-10-29 2015-07-22 中国科学院昆明植物研究所 C-3,11,12,20-四取代c-21甾体类衍生物及其药物组合物和其在医药中的应用
WO2014085668A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Anticonvulsant activity of steroids
PT2935307T (pt) * 2012-12-18 2018-07-31 Univ Washington Esteroides 19-alcoxi-17-substituídos neuroativos, úteis em métodos de tratamento
EP2956466A4 (en) * 2013-02-15 2016-11-02 Univ Washington NEUROACTIVE ENANTIOMERS 15, 16 AND 17 SUBSTITUTED STEROIDS AS MODULATORS FOR GABA-A RECEPTORS
US9512170B2 (en) 2013-03-01 2016-12-06 Washington University Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors
US9365502B2 (en) 2013-03-11 2016-06-14 Washington University Neuroactive substituted cyclopenta[b]phenanthrenes as modulators for GABA type-A receptors
MX362544B (es) * 2013-03-13 2019-01-24 Sage Therapeutics Inc Esteroides neuroactivos y metodos para su uso.
US9562026B2 (en) 2013-03-14 2017-02-07 Washington University Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US20160068563A1 (en) 2013-04-17 2016-03-10 Boyd L. Harrison 19-nor neuroactive steroids and methods of use thereof
TR201901745T4 (tr) 2013-04-17 2019-03-21 Sage Therapeutics Inc 19-nor C3,3-disübstitüe edilmiş C21- n-pirazolil steroidleri ve bunların kullanım yöntemleri.
SI2986624T1 (sl) 2013-04-17 2020-10-30 Sage Therapeutics, Inc. 19-nor nevroaktivni steroidi za metode zdravljenja
PL3021852T3 (pl) 2013-07-19 2021-07-05 Sage Therapeutics, Inc. Neuroaktywne steroidy, kompozycje i ich zastosowania
PT3035940T (pt) 2013-08-23 2019-01-28 Sage Therapeutics Inc Esteroides neuroativos, composições e seus usos
EP4306114A1 (en) 2014-06-18 2024-01-17 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
EP3188734A4 (en) 2014-09-02 2018-01-10 The Texas A&M University System Method of treating organophosphate intoxication
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
KR20230170816A (ko) 2014-10-16 2023-12-19 세이지 테라퓨틱스, 인크. Cns 장애의 치료를 위한 조성물 및 방법
PT3206493T (pt) 2014-10-16 2020-08-03 Sage Therapeutics Inc Composições e métodos para tratamento de transtornos do snc
JP6893173B2 (ja) 2014-11-27 2021-06-23 セージ セラピューティクス， インコーポレイテッド Ｃｎｓ障害を処置するための組成物および方法
AR103384A1 (es) 2015-01-12 2017-05-03 Umecrine Cognition Ab 3a-ETINILO, 3b-HIDROXI, 5a-PREGNAN-20-OXIMA COMO MODULADOR DE GABA
HUE054092T2 (hu) 2015-01-26 2021-08-30 Sage Therapeutics Inc Központi idegrendszeri zavarok kezelésére szolgáló kompozíciók és eljárások
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
HK1255500A1 (zh) 2015-07-06 2019-08-16 Sage Therapeutics, Inc. 氧固醇及其使用方法
EP3828194B1 (en) * 2015-07-06 2025-04-16 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
PL3319612T3 (pl) * 2015-07-06 2021-12-20 Sage Therapeutics, Inc. Oksysterole i sposoby ich stosowania
RU2766155C2 (ru) 2016-03-08 2022-02-08 Сейдж Терапьютикс, Инк. Нейроактивные стероиды, их композиции и применения
US20190330259A1 (en) 2016-04-01 2019-10-31 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10752653B2 (en) 2016-05-06 2020-08-25 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
MD3481846T2 (ro) 2016-07-07 2021-11-30 Sage Therapeutics Inc 24-Hidroxisteroli 11-substituiți pentru utilizare în tratamentul stărilor legate de NMDA
NZ790226A (en) 2016-07-11 2025-08-29 Sage Therapeutics Inc C17, C20, and C21 substituted neuroactive steroids and their methods of use
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
CN106265685A (zh) * 2016-09-18 2017-01-04 南通大学 没药甾酮z在制备抗抑郁症药物中的应用
CN121085986A (zh) 2016-09-30 2025-12-09 萨奇治疗股份有限公司 C7取代的氧固醇及其作为nmda调节剂的方法
TW202444381A (zh) 2016-10-18 2024-11-16 美商賽吉醫療公司 氧固醇(oxysterol)及其使用方法
KR102521573B1 (ko) 2016-10-18 2023-04-14 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
WO2019075362A1 (en) * 2017-10-12 2019-04-18 Sage Therapeutics, Inc. METHOD OF TREATING CENTRAL NERVOUS SYSTEM DISORDERS WITH NEUROSTEROIDS AND GABAERGIC COMPOUNDS
US11718642B2 (en) 2018-01-12 2023-08-08 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
MX2020008422A (es) * 2018-02-11 2020-09-21 Jiangsu Hansoh Pharmaceutical Group Co Ltd Regulador derivado de esteroides, metodo para prepararlos y usos de los mismos.
BR112020015131A2 (pt) * 2018-02-11 2021-01-05 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Reguladores derivados de esteroide, método para preparar os mesmos, e usos dos mesmos
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
CN116589521B (zh) * 2019-01-08 2025-07-11 成都康弘药业集团股份有限公司 甾体类化合物、用途及其制备方法
CN114206900A (zh) * 2019-05-31 2022-03-18 萨奇治疗股份有限公司 神经活性类固醇及其组合物
WO2021188778A2 (en) * 2020-03-18 2021-09-23 Sage Therapeutics, Inc. Neuroactive steroids and their methods of use
MX2022013904A (es) * 2020-05-18 2023-01-04 Vistagen Therapeutics Inc Tratamiento de trastornos de adaptacion.
RU2739247C1 (ru) * 2020-09-14 2020-12-22 Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" Способ получения лекарственного препарата для парентерального применения
WO2023060067A1 (en) 2021-10-04 2023-04-13 Marinus Pharmaceuticals, Inc. Amorphous solid dispersion ganaxolone formulation
WO2023083980A1 (en) 2021-11-10 2023-05-19 Umecrine Ab Steroid as a modulator of gabaa receptor
CA3237550A1 (en) 2021-11-10 2023-05-19 Umecrine Ab 3.alpha.-substituted 3.beta.-hydroxy 17-oximated androstane compound for modulation of the alpha-3 subtype of the gaba-a receptor
EP4430056A1 (en) 2021-11-10 2024-09-18 Umecrine AB 3.beta.-hydroxy, 3.alpha.-ethyl steroids for modulation of the alpha-3 subtype of the gaba-a receptor
US20240408124A1 (en) 2023-05-31 2024-12-12 Rubedo Life Sciences, Inc. GPX4 Inhibitors and Senolytic Compounds and Uses Thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1050765B (de) * 1959-02-19 Les Laboratoires Fran?ais de Chimiotherapie, Paris Verfahren zur Herstellung von Testan-3a-ol-ll-on und seinen Estern
GB839911A (en) * 1957-01-29 1960-06-29 Chimiotherapie Lab Franc Derivatives of etiocholane and the preparation thereof
US3135744A (en) * 1961-04-12 1964-06-02 Vismara Francesco Spa Cycloalkenyl ethers of 17 beta-hydroxy androstanes
FR1437361A (fr) * 1962-06-28 1966-05-06 Vismara Francesco Spa Procédé de préparation de nouveaux éthers alcényliques de 17beta-hydroxy-androstanes
US3316146A (en) * 1964-03-30 1967-04-25 Upjohn Co Method of inducing sedation and muscle relaxation
GB1376892A (en) * 1970-11-12 1974-12-11 Glaxo Lab Ltd 2beta-substituted-3alpha-hydroxysteroids and their esters
GB1380248A (en) * 1970-12-17 1975-01-08 Glaxo Lab Ltd 3alpha-hydroxy steroids and esters thereof
US3969345A (en) * 1970-12-17 1976-07-13 Glaxo Laboratories Limited 20β,21-Epoxy-3α-hydroxy-5α-pregnanes and derivatives thereof
US3943124A (en) * 1970-12-17 1976-03-09 Gordon Hanley Phillipps Chemical compounds
US3953429A (en) * 1970-12-17 1976-04-27 Glaxo Laboratories Limited Anaesthetic steroids of the androstance and pregnane series
GB1377608A (en) * 1970-12-17 1974-12-18 Glaxo Lab Ltd 3alpha-hydroxy or acyloxy pregnene-21-ethers
GB1409239A (en) * 1971-11-11 1975-10-08 Glaxo Lab Ltd Process for the preparation of 3alpha-hydroxy-5alpha-steroids
GB1432135A (en) * 1972-05-05 1976-04-14 Glaxo Lab Ltd 21-substituted pregnanes
US3959260A (en) * 1972-05-05 1976-05-25 Glaxo Laboratories Limited Anaesthetic steroids of the pregnane and 19-norpregnane series having a sulfur-containing group at the 21-position
GB1436324A (en) * 1972-05-12 1976-05-19 Glaxo Lab Ltd Anaesthetic 3alpha-hydroxy pregnanes
US4192871A (en) * 1976-01-06 1980-03-11 Glaxo Laboratories Limited Chemical compounds
US4197296A (en) * 1977-03-23 1980-04-08 Glaxo Group Limited Androstanes
GB1581235A (en) * 1977-04-04 1980-12-10 Glaxo Operations Ltd 11a-amino-3a-hydroxy-steroids
US4297350A (en) * 1978-10-10 1981-10-27 The Upjohn Company Male contraceptive steroids and methods of use
US5208227A (en) * 1987-08-25 1993-05-04 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5319115A (en) * 1987-08-25 1994-06-07 Cocensys Inc. Method for making 3α-hydroxy, 3β-substituted-pregnanes
EP0701444B1 (en) * 1993-05-24 2010-04-07 Purdue Pharma Ltd. Methods and compositions for inducing sleep
PT752860E (pt) * 1994-02-14 2000-12-29 Euro Celtique Sa Androstanos e pregnanos para modulacao alosterica do receptor de gaba
CN1171114A (zh) * 1994-11-23 1998-01-21 科斯赛斯公司 用于γ-氨基丁酸受体的变构调节的雄甾烷和孕甾烷组系

Also Published As

Publication number Publication date
DE69634039D1 (de) 2005-01-20
AU6172596A (en) 1996-12-30
MX9709384A (es) 1998-10-31
CN1190404A (zh) 1998-08-12
HUP9901138A2 (hu) 1999-07-28
PL185523B1 (pl) 2003-05-30
FI974448A7 (fi) 1997-12-05
CA2223996A1 (en) 1996-12-19
BR9608592A (pt) 1999-06-29
EP0837874B1 (en) 2004-12-15
WO1996040043A2 (en) 1996-12-19
JPH11507643A (ja) 1999-07-06
JP4145350B2 (ja) 2008-09-03
UA57706C2 (uk) 2003-07-15
NO311805B1 (no) 2002-01-28
KR19990022323A (ko) 1999-03-25
HUP9901138A3 (en) 1999-11-29
US5925630A (en) 1999-07-20
ES2235187T3 (es) 2005-07-01
NO975608D0 (no) 1997-12-04
WO1996040043A3 (en) 1997-03-27
RU2194712C2 (ru) 2002-12-20
ATE284895T1 (de) 2005-01-15
CZ394197A3 (cs) 1998-06-17
FI974448L (fi) 1997-12-05
NZ310850A (en) 1999-07-29
EP1288220A2 (en) 2003-03-05
PL323718A1 (en) 1998-04-14
IL122348A0 (en) 1998-04-05
AU725214B2 (en) 2000-10-05
EP0837874A2 (en) 1998-04-29
GEP20012530B (en) 2001-09-25
FI974448A0 (fi) 1997-12-05
NO975608L (no) 1998-02-06
DE69634039T2 (de) 2005-12-08
EP1288220A3 (en) 2004-07-21

Similar Documents

Publication Publication Date Title
PT837874E (pt) Esteroides neuroactivos da serie androstano e pregnano
DE122012000012I1 (de) 17-Substituierte steroide, verwendbar bei behandlung von krebs.
DE69326805D1 (de) 17-Spiromethylensteroide
DE69205405D1 (de) 17-Spirofuran-3'-Yliden Steroide.
PT78743A (de) 1-alkyl-androsta-1,4-dien-3,17-dione verfahren zu deren herstellung und diese enthaltende pharmazeutische praeparate
CA2382489A1 (en) Non-aromatic estrogenic steroids with a hydrocarbon substituent in position 11
ATE152119T1 (de) Neue 16-methyl substituierte steroidderivate von pregna-1,4-dien-3,20-dion, ihre herstellung, ihre verwendung zur herstellung von 16-methylene- substituierte steroide und neue zwischenprodukten dafür
ATE154606T1 (de) 2beta,19-methylenamin überbrückte steroide als aromatasehemmer
IE38909L (en) Steroid carbamates and allophanates.
DE60331572D1 (de) Stereospezifische reduktion von sapogen-3-onen
PT1196428E (pt) Esteroides substituidos com 11 beta-aril-17, 17-espirotiolano
ATE81508T1 (de) Herstellung von corticoiden aus steroidischen 17- cyanohydrinen.
GB1427645A (en) Pregnane derivative its preparation and compositions thereof
NO944999D0 (no) Fremgangsmåte for steroide peracylglykosider
GB862621A (en) Improvements in or relating to 4-organothiomethyl-3-oxo-delta-steroids
NZ333837A (en) estrene steroids for inducing hypothalamic effects